Kura Oncology (KURA) Research & Development (2014 - 2026)
Kura Oncology (KURA) reported Research & Development of $65.3 million for Q1 2026, up 16.6% year-over-year from $56.0 million in Q1 2025, and up 16.6% on a QoQ basis from $56.0 million in Q1 2025.
Kura Oncology (KURA) has 11 years of Research & Development data on file, last reported at $65.3 million in Q1 2026.
- Quarterly Research & Development rose 16.6% year-over-year to $65.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $215.2 million (up 13.46% YoY) and the FY2025 annual result came in at $251.1 million, up 47.72% from the prior year.
- Research & Development advanced to $65.3 million in Q1 2026 per KURA's latest filing, from $56.0 million in the prior quarter.
- Across five years, Research & Development topped out at $65.3 million in Q1 2026 and bottomed at $20.9 million in Q1 2022.
- The 5-year median for Research & Development is $30.9 million (2023), against an average of $35.7 million.
- The widest annual swing landed in 2022, when Research & Development gained 2.9%; it then surged 60.66% in 2024.
- Tracing KURA's Research & Development over 5 years: stood at $22.7 million in 2022, then surged by 43.52% to $32.5 million in 2023, then surged by 60.66% to $52.3 million in 2024, then rose by 7.09% to $56.0 million in 2025, then increased by 16.6% to $65.3 million in 2026.
- Per Business Quant, the three latest KURA Research & Development figures stand at $65.3 million (Q1 2026), $56.0 million (Q1 2025), and $52.3 million (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn | 65.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65.26 Mn |
| Mar 31, 2025 | 55.97 Mn |
| Dec 31, 2024 | 52.27 Mn |
| Sep 30, 2024 | 41.71 Mn |
| Jun 30, 2024 | 39.73 Mn |
| Mar 31, 2024 | 36.27 Mn |
| Dec 31, 2023 | 32.53 Mn |
| Sep 30, 2023 | 29.33 Mn |
| Jun 30, 2023 | 28.18 Mn |
| Mar 31, 2023 | 25.19 Mn |
| Dec 31, 2022 | 22.67 Mn |
| Sep 30, 2022 | 24.97 Mn |
| Jun 30, 2022 | 24.26 Mn |
| Mar 31, 2022 | 20.91 Mn |
| Dec 31, 2021 | 20.96 Mn |
| Sep 30, 2021 | 22.37 Mn |
| Jun 30, 2021 | 21.07 Mn |
| Mar 31, 2021 | 20.32 Mn |
| Dec 31, 2020 | 17.52 Mn |
| Sep 30, 2020 | 16.60 Mn |
| Jun 30, 2020 | 13.70 Mn |
| Mar 31, 2020 | 12.58 Mn |
| Dec 31, 2019 | 13.46 Mn |
| Sep 30, 2019 | 12.54 Mn |
| Jun 30, 2019 | 11.44 Mn |
| Mar 31, 2019 | 10.38 Mn |
| Jun 30, 2016 | 1.00 Mn |
| Mar 31, 2016 | 1.20 Mn |
| Dec 31, 2015 | -5.49 Mn |
| Sep 30, 2015 | 3.64 Mn |
| Jun 30, 2015 | 1.10 Mn |
| Mar 31, 2015 | 1.10 Mn |
| Dec 31, 2014 | 130,000.00 |
| Sep 30, 2014 | 3,000.00 |